Fig. 2From: The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decadesThe evolving treatment landscape of B-ALL. Abbreviations: FL, frontline; InO, inotuzumab ozogamicin; MRD, measurable residual disease; Ph, Philadelphia chromosome; R/R, relapsed/refractory; SOC, standard of careBack to article page